MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

Twist Bioscience Corp

Fechado

SetorSaúde

42.5 0.47

Visão Geral

Variação de preço das ações

24h

Atual

Mín

41.62

Máximo

43.09

Indicadores-chave

By Trading Economics

Rendimento

-48M

-27M

Vendas

3M

99M

Margem de lucro

-27.41

Funcionários

979

EBITDA

3.2M

-21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+0.14% upside

Dividendos

By Dow Jones

Próximos Ganhos

2 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

669M

2.5B

Abertura anterior

42.03

Fecho anterior

42.5

Sentimento de Notícias

By Acuity

50%

50%

148 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jan. de 2026, 23:07 UTC

Ganhos

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 de jan. de 2026, 21:27 UTC

Ganhos

Texas Instruments 4Q Sales Rise, Profit Falls

27 de jan. de 2026, 23:55 UTC

Conversa de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 de jan. de 2026, 23:39 UTC

Conversa de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation Posts Net Loss for Second Consecutive Year

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 de jan. de 2026, 23:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 de jan. de 2026, 22:17 UTC

Conversa de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 de jan. de 2026, 22:06 UTC

Ganhos

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 de jan. de 2026, 21:51 UTC

Ganhos

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de jan. de 2026, 21:43 UTC

Ganhos

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 de jan. de 2026, 21:41 UTC

Ganhos

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 de jan. de 2026, 21:38 UTC

Ganhos

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: Modest Profit From F&I International in 2025

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 de jan. de 2026, 21:30 UTC

Ganhos

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 de jan. de 2026, 21:28 UTC

Ganhos

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

0.14% parte superior

Previsão para 12 meses

Média 43 USD  0.14%

Máximo 50 USD

Mínimo 39 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

148 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat